IP Group Reports Strong H1 Performance with NAV Growth and Cash Realizations
IP Group reported a strong first-half performance in 2026, marked by an increase in net asset value (NAV) per share of 3.2% to 114p, pushing total NAV above £1 billion. The rise was largely driven by the higher valuation of its Oxford Nanopore holding and gains from a royalty interest in Pfizer's obesity treatment programs. Management noted that cash proceeds reached £69 million during the half-year period and £86 million year-to-date, with exits including Hinge Health, Monolith, and Centessa contributing significantly. The company is targeting total realizations of £250 million by 2027 as part of its strategy to convert portfolio value into shareholder returns. The Pfizer royalty interest saw a valuation increase of £27 million due to the advancement of berobenatide combination therapy into Phase IIb trials, with positive preliminary data reported and plans for multiple Phase III studies in progress. Portfolio companies also raised over £500 million from third-party investors during the half-year. Management is evaluating how best to utilize approximately £50 million in available proceeds to enhance shareholder returns while maintaining a focus on long-term value creation.
Tickers: $PFE